BioAgilytix, a leading provider of contract bioanalytical services, has validated 20 key oncology biomarkers in an effort to expedite the search for a cure. These validated assays will allow drug developers in the pharmaceutical and biotechnology industries to cut costs and save time as they develop their therapeutics and push for regulatory approval.
BioAgilytix has supported oncology development as a core service since inception in 2008, with a scientific team boasting more than 100 publications in the oncology arena. “The addition of these 20 key validated biomarkers will have a profound effect on BioAgilytix’s ability to support oncology therapeutics,” notes Afshin Safavi, Ph.D., Chief Scientific Officer at BioAgilytix. “The biomarkers we have invested in are truly some of the key assays that most drug developers and regulatory agencies look for in support of oncology drug development. Our heavy investment in this area proves our commitment to help our clients in finding cures for cancer, and solidifies our laboratory as the go-to bioanalytical lab in terms on oncology drug development.”
The new validated biomarker offerings include: IGFBP-2, M30, M65, cKit, KDR (VEGFR2), VEGF, VEGF-C, VEGF-D, Tie-2, PlGF, sFlt (VEGFR1), bFGF, IGF-II, HSP-70, PARP, TGF-β1, cAMP, CRP, Ferritin, GDF-15, IL-6R. Validation reports are available upon request.
About BioAgilytix www.bioagilytix.com
BioAgilytix is a leading bioanalytical testing laboratory specializing in large-molecule bioanalysis. Located in North Carolina’s Research Triangle, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assays services supporting the development and release testing of biologics and small molecule therapeutics. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, spirit-of-GLP, and GLP, as well as product release testing under GMP.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, sample and data integrity, and regulatory compliance through all phases of clinical development, acting as a trusted partner to 6 of the top 10 global pharmaceutical and biotech companies.
Matthew Hoyle, Marketing Manager